What is the ticker symbol for Traws Pharma?

Traws Pharma trades under the ticker TRAW on NASDAQ.

What sector does Traws Pharma operate in?

Traws Pharma is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze TRAW in a portfolio?

PortView shows TRAW's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

Traws Pharma (TRAW) Stock Analysis

NASDAQHealthcareBiotechnology

$0.59+0.73%

1-year price historyRange $0.44 – $3.13

52-week range$0.59

$0.43$3.27

What Traws Pharma does

Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includes experimental treatments specifically designed to overcome drug resistance in influenza and COVID-19. These promising candidates include TRX01 (travatrelvir), an Mpro/3CL inhibitor currently undergoing development for COVID-19, and TRX100 (viroxavir), an endonuclease inhibitor advancing through trials for pandemic influenza. Additionally, Traws Pharma's oncology portfolio features narazaciclib, a multi-kinase CDK4/6 inhibitor. This compound is presently in Phase 1/2 clinical trials in cancer patients, being evaluated both independently and in conjunction with letrozole, with the goal of establishing the recommended Phase 2 dosage for future work in endometrial cancer. The company is also investigating oral rigosertib, exploring its potential as a standalone therapy or in combination regimens across diverse cancer types. Originally established in 1998 as Onconova Therapeutics, Inc., the company officially adopted its current name, Traws Pharma, Inc., in April 2024. Its corporate headquarters are located in Newtown, Pennsylvania.

Key metrics

Market cap

$9.05M

P/E (TTM)

-0.48

EPS (TTM)

$-1.24

Beta

1.56

Dividend yield

0.00%

Revenue / share

$0.00

50-day avg

$0.62

200-day avg

$1.45

52-week high

$3.27

52-week low

$0.43

CEO

Iain D. Dukes

ETFs linked to TRAW

Broad-market and Healthcare sector ETFs an investor holding Traws Pharma is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how TRAW fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze TRAW in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for Traws Pharma?: Traws Pharma trades under the ticker TRAW on NASDAQ.
Which exchange is TRAW listed on?: TRAW is listed on NASDAQ.
What sector does Traws Pharma operate in?: Traws Pharma is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze TRAW in a portfolio?: PortView shows TRAW's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.